- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03919890
A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers
December 6, 2019 updated by: Ono Pharmaceutical Co. Ltd
A First-in-human, Randomised, Placebo-controlled, Double-blind, Single and Multiple Dose Study to Explore the Safety, Tolerability, PK and PD of Oral Doses of ONO-7684 in Healthy Subjects Under Fed and Fasted Conditions
This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-7684 in healthy adult volunteers.
This study will be conducted in 2 parts: Part A is a single-ascending dose and Part B is a multiple-ascending dose.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study aims to obtain safety, tolerability, pharmacokinetic and pharmacodynamic data when ONO-7684 is administered orally as single doses and as multiple doses to healthy subjects.
The study will consist of 2 parts: A single ascending dose (SAD) phase (Part A); a multiple ascending dose (MAD) phase (Part B).
One cohort of Part A will receive ONO-7684 under both fasted and fed conditions to investigate the effect of food.
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, NW10 7EW
- Hammersmith Medicines Research (HMR)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-55 years
- normotensive male volunteers, or female volunteers of non-childbearing potential (Part B only)
- body mass index 18.0-30.0 kg/m2
- deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine
- registered with a General Practitioner (GP) in the UK
- agree to use an effective method of contraception
- able to give fully informed written consent
Exclusion Criteria:
- Positive tests for hepatitis B & C, HIV
- severe adverse reaction to any drug
- sensitivity to trial medication
- drug or alcohol abuse
- current smoker or use of nicotine containing products in the previous 6 months
- vegetarians or vegans, or unwilling to eat a high-fat breakfast (Part A food effect cohorts only)
- use of strong CYP3A4/5 or P-glycoprotein inhibitors or inducers, anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs and/or acetylsalicylic acid within the previous 30 days
- prescription or over-the-counter medication, vitamins, herbal treatments or dietary supplements within the previous 7 days (with the exception of paracetamol [acetaminophen])
- participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months or plan to donate blood or blood products in the 3 months after the trial
- vital signs outside the acceptable range
- clinically relevant abnormal findings at the screening assessment (including creatinine clearance, haemoglobin levels and QTcF)
- acute or chronic illness
- clinically relevant abnormal medical history or concurrent medical condition
- objection by GP
- possibility that volunteer will not cooperate
- pre-menopausal females who are pregnant or lactating, or who are of childbearing potential
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ONO-7684 Part A1
Single ascending doses of ONO-7684 or placebo orally under fasted conditions
|
Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
|
Placebo Comparator: ONO-7684 Placebo Part A1
Single ascending doses of ONO-7684 or placebo orally under fasted conditions
|
Placebo comparator
|
Experimental: ONO-7684 Part A2
Single doses of ONO-7684 or placebo orally under fed conditions
|
Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
|
Placebo Comparator: ONO-7684 Placebo Part A2
Single doses of ONO-7684 or placebo orally under fed conditions
|
Placebo comparator
|
Experimental: ONO-7684 Part B1
Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
|
Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
|
Placebo Comparator: ONO-7684 Placebo Part B1
Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
|
Placebo comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with clinically significant changes in vital signs (Part A & B)
Time Frame: Part A: Day 1-4 & Follow-up and Part B: Day 1-15, 17 & Follow up
|
Pulse rate (bpm), systolic and diastolic blood pressure (mmHg), Respiratory rate (bpm)
|
Part A: Day 1-4 & Follow-up and Part B: Day 1-15, 17 & Follow up
|
Number of participants with clinically significant changes observed on 12-lead electrocardiogram (ECG) (Part A & B)
Time Frame: Part A: Day 1-4 & Follow up & Part B: Day 1,3,5,7,9,11,14,17 & Follow up
|
Ventricular rate (beats/min), PR interval (msec), QRS interval (msec), QT (msec), QTcF interval (msec)
|
Part A: Day 1-4 & Follow up & Part B: Day 1,3,5,7,9,11,14,17 & Follow up
|
Number of participants with clinically significant changes in cardiac telemetry (Part A only)
Time Frame: Part A: From 0.5-1 hours pre-dose until 12 hours after dosing at Day 1
|
Number of participants with cardiac telemetry abnormalities will be reported.
|
Part A: From 0.5-1 hours pre-dose until 12 hours after dosing at Day 1
|
Number of participants with clinically significant changes in physical examination (Part A & B)
Time Frame: Part A: Day -1, 1-4 & Follow-up and Part B: Day-1, 1-17 & Follow up
|
Number of participants with physical examination abnormalities will be reported.
|
Part A: Day -1, 1-4 & Follow-up and Part B: Day-1, 1-17 & Follow up
|
Number of participants with clinically significant changes in laboratory safety tests (haematology, biochemistry and urinalysis) (Part A & B)
Time Frame: Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up
|
Number of participants with abnormalities in laboratory safety tests will be reported.
|
Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up
|
Number of participants with adverse events (AE) (Part A & B)
Time Frame: Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up
|
AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
|
Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (Cmax)
Time Frame: Part A: Day 1 through Day 4. Part B: Day 1 and Day 14
|
Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 1 and Day 14
|
Pharmacokinetics (tmax)
Time Frame: Part A: Day 1 through Day 4. Part B: Day 1 and Day 14
|
Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 1 and Day 14
|
Pharmacokinetics (AUClast)
Time Frame: Part A: Day 1 through Day 4. Part B: Day 14
|
Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 14
|
Pharmacokinetics (AUCinf)
Time Frame: Part A: Day 1 through Day 4. Part B: Day 14
|
Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 14
|
Pharmacokinetics (AUCt)
Time Frame: Part A: Day 1 through Day 4. Part B: Day 1
|
Assessment of the area under the curve of concentration of ONO-7684 and 3-hydroxybenzoic acid - time from zero up to a definitive time, t in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 1
|
Pharmacokinetics (%AUCextrap)
Time Frame: Part A: Day 1 through Day 4. Part B: Day 14
|
Assessment of the percentage of AUC∞ extrapolated from tlast to infinity of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 14
|
Pharmacokinetics (t1/2)
Time Frame: Part A: Day 1 through Day 4. Part B: Day 14
|
Assessment of the elimination half-time of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 14
|
Pharmacokinetics (CL/F)
Time Frame: Day 1 through Day 4
|
Assessment of the apparent clearance rate of ONO-7684 and 3-hydroxybenzoic acid in Part A only
|
Day 1 through Day 4
|
Pharmacokinetics (Terminal Rate Constant)
Time Frame: Day 1 through Day 4
|
Assessment of the terminal rate constant (slowest rate constant of the disposition) of ONO-7684 and 3-hydroxybenzoic acid in plasma in Part A only
|
Day 1 through Day 4
|
Pharmacokinetics (Aet)
Time Frame: Day 1 through Day 4
|
Assessment of the amount of ONO-7684 excreted in urine over the period of sample collection in Part A only
|
Day 1 through Day 4
|
Pharmacokinetic (fe/F)
Time Frame: Day 1 through Day 4
|
Assessment of the fraction of orally administered ONO-7684 excreted into urine in Part A only
|
Day 1 through Day 4
|
Pharmacokinetic (CLr)
Time Frame: Day 1 through Day 4
|
Assessment of the renal clearance of ONO-7684 from plasma in Part A only
|
Day 1 through Day 4
|
Pharmacokinetic (Ctrough)
Time Frame: Day 1 through Day 14
|
Assessment of the trough plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Part B only
|
Day 1 through Day 14
|
Pharmacokinetic (AUCtau)
Time Frame: Day 14
|
Assessment of the area under the plasma concentration of ONO-7684 and 3-hydroxybenzoic acid -time during a dosing interval in Part B only
|
Day 14
|
Pharmacokinetic (CLSS/F)
Time Frame: Day 14
|
Assessment of total clearance of ONO-7684 from plasma after oral administration in Part B only
|
Day 14
|
Pharmacokinetic (VZ/F)
Time Frame: Day 14
|
Assessment of apparent volume of distribution of ONO-7684 after non-intravenous administration calculated at steady state in Part B only
|
Day 14
|
Pharmacodynamic (change from baseline in aPTT activity) in serum
Time Frame: Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Assessment of the effect of ONO-7684 in activated partial thromboplastin time in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Pharmacodynamic (change from baseline in PT activity) in serum
Time Frame: Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Assessment of the effect of ONO-7684 in prothrombin time in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Pharmacodynamic (change from baseline in PT-INR activity) in serum
Time Frame: Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Assessment of the effect of ONO-7684 in prothrombin time-international normalised ratio in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Pharmacodynamic (change from baseline in FXIa activity) in serum
Time Frame: Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Assessment of the effect of ONO-7684 in blood coagulation activated factor XI in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Pharmacodynamic (correlation of aPTT and FXIa activity) in serum
Time Frame: Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Assessment of the effect of ONO-7684 in the correlation of activated partial thromboplastin time to blood coagulation activated factor XI in Parts A and B
|
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 17, 2019
Primary Completion (Actual)
August 23, 2019
Study Completion (Actual)
August 23, 2019
Study Registration Dates
First Submitted
March 14, 2019
First Submitted That Met QC Criteria
April 15, 2019
First Posted (Actual)
April 18, 2019
Study Record Updates
Last Update Posted (Actual)
December 9, 2019
Last Update Submitted That Met QC Criteria
December 6, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONO-7684-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on ONO-7684
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharma USA IncCompleted
-
Ono Pharmaceutical Co. LtdTerminatedPain | Osteoarthritis, KneePoland, Hungary, Spain, Denmark, United Kingdom
-
Ono Pharma USA IncCompletedIrritable Bowel Syndrome (IBS)United States
-
Ono Pharmaceutical Co. LtdCompletedOsteoarthritisDenmark, United Kingdom
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharma USA IncCompletedMajor Depressive DisorderUnited States
-
Ono Pharmaceutical Co. LtdRecruitingLymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-CellUnited States
-
Ono Pharma USA IncCompletedDiabetes Mellitus, Type 2United States